← Return to all swing-trade opportunities
TGTX — Trend Pullback to 20 EMA
Status: Invalidated
Scanner score: 65.0/100
Why this was flagged
TGTX was identified as a bullish technical setup based on the Trend Pullback to 20 EMA pattern. The scanner found a score of 65.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found TG Therapeutics Inc (TGTX) using a pattern called a Trend Pullback to 20 EMA. This means the stock has been moving up, but it recently dipped back down toward its 20-day Exponential Moving Average (EMA). An EMA is a line that shows the average price over a certain number of days. The scanner gave this setup a score of 65 out of 100. It noticed that the price is sitting above its 20, 50, and 200-day moving averages. This shows the long-term direction is upward. The Relative Strength Index (RSI) is also in a good range, meaning it is not "overbought" or too expensive yet.
What the price plan means
The entry zone is between $56.04 and $56.67. If you use a stop-loss, that is a price set at $52.25 to limit losses if the price drops. The first goal for the price is $63.62, and the second goal is $67.41. This plan has a reward-to-risk ratio of 2, which means the potential gain is twice as large as the potential loss.
What could make the idea fail
The stock's relative volume is 0.61, which means it is trading with less activity than usual. If there is not enough interest from buyers, the price might not move up as expected.
Important reminder
This information is for educational purposes only.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (High confidence)
TG Therapeutics (TGTX) shows mixed signals. On one hand, the company reported significant revenue growth in its 'Novel Treatments for B-cell Diseases' segment and received a price target increase from TD Cowen to $75. Some analysts suggest the stock may be undervalued based on earnings multiples. However, these positives are offset by notable risks, including an investigation by Kuehn Law, PLLC into potential self-dealing by officers and directors, and heavy revenue concentration in its BRIUMVI drug. Additionally, analyst views on fair value vary significantly, with some suggesting the stock is overvalued or facing competitive pressures.
Potentially supportive context
- Revenue from 'Novel Treatments for B-cell Diseases' increased to 524.72 million EUR from 317.81 million EUR the previous year.
- TD Cowen raised its price target for TGTX from $50 to $75.
- Some analysis indicates the stock may be undervalued based on a P/E of 17.2x against a fair estimate of 24.1x.
Risks and caution items
- Kuehn Law, PLLC is investigating whether officers and directors breached fiduciary duties through potential self-dealing.
- High revenue concentration risk due to reliance on the drug BRIUMVI.
- Conflicting analyst views regarding valuation and competitive pressures.
- Potential for corporate governance reforms following legal investigations.
Latest reviewed article: Jul 25, 2026 5:40 pm
Recent related articles
This article provides a revenue breakdown for TG Therapeutics Inc (TGTX), detailing its business segments for the fiscal year 2024. The majority of the company's revenue, 98.48%, comes from total product revenue, net, followed by royalty revenue and other revenue. The report…
TG Therapeutics, Inc. (A1JXW7) generated 524.72 million EUR in revenue last year, primarily from its "Novel Treatments for B-cell Diseases" segment, which also contributed the same amount. This represents a significant increase from the previous year's 317.81 million EUR. The United States…
TG Therapeutics (TGTX) stock has seen significant returns over the past three years but still screens as undervalued based on earnings multiples, trading at a P/E of 17.2x against a fair estimate of 24.1x. The company's valuation presents a mixed picture due…
This page provides fundamental and financial data for TG Therapeutics Inc (TGTX), listed on NASDAQ. Key figures include a market capitalization of $8.5 billion, a current price of $56.04, and upcoming earnings on August 3. The article also highlights recent news, such…
This article provides the latest stock information for TG Therapeutics Inc. (TGTX), including its current stock price, market capitalization, key financial metrics, upcoming earnings date, and recent news headlines. It also highlights top discussions on other trending stocks like GOOGL, SMCI, and…
This article analyzes Tg Therapeutics Inc. (NASDAQ: TGTX), noting weak near-term sentiment but strong long-term potential with no resistance levels above the current price. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis…
TG Therapeutics' stock (TGTX) is currently trading at US$52.68, which is 1.9% overvalued compared to the analyst consensus fair value of US$51.71. Analyst price targets range from a low of US$20 to a high of US$83, reflecting differing views on the company's…
TD Cowen has increased its target price for TG Therapeutics Inc. (TGTX.O) shares to $75 from $50. This update indicates a significant positive re-evaluation of the company's stock by the financial firm.
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Price is above the 20-, 50-, and 200-day moving averages, with bullish moving-average alignment.
- RSI is in a constructive momentum range without being overbought.
- Price is near the 20 EMA in a bullish trend and the current candle is positive.